Objective: To explore the effect of hemodialysis plus calcitriol on cardiac function and BNP in patients with hyperparathyroidism secondary to nephropathy. Methods: In this retrospective study, a total of 80 patients with nephropathy secondary to hyperparathyroidism treated in our hemodialysis center from January 2018 to January 2020 were included. The patients were divided into a combination group (n=50) and a control group (n=30) ac-cording to treatment plan. Both groups were treated with hemodialysis, and the combination group was treated with additional calcitriol. The heart rate, heart functions such as left ventricular end-systolic volume (LVESV), left ventricular ejection fraction (LVEE), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic di-ameter (LVESD), brain natriuretic peptide (BNP) level, blood calcium and phosphorus level, intact parathyroid hor-mone (iPTH) and alkaline phosphatase (ALP) level, total effective rate, and adverse reaction rate of the two groups were compared. Results: Compared to the control group, the heart rate, LVEE, LVEDD and LVESD, BNP level, blood calcium and phosphorus level, and the incidence of adverse reactions of the combination group were lower, while LVESV level, iPTH, and ALP levels, and the total effective rate were higher. Conclusion: Hemodialysis combined with calcitriol can better improve cardiac function and BNP level of patients than hemodialysis alone.